Abstract:The blood-brain barrier (BBB) has a key role in preventing drugs from entering the brain. Non-invasive intranasal drug delivery routes that bypass the BBB are increasing in popularity because of their ability to shorten the journey and reduce the loss of genetic drugs such as siRNA in transit. However, the com-plex synthesis and quality control process of most nose-to-brain delivery carriers and the limited mass production are the main obstacles to their clinical application. Here, we constructed a siRNA delivery system with simple synthesis and quality control methods using cholesterol-modified T7 (T7-C), in which T7 can bind to the transferrin receptor (TfR) expressed on glioma cells to target gliomas. In our results, T7-C had dual functions as a glioma-targeting carrier and immune adjuvant. As a targeted delivery car-rier, T7-C intranasally delivered siRNA into the mouse brain through the olfactory bulb pathway and was taken up by glioma cells by the caveolin-and transferrin-dependent pathway. As an immune adjuvant, T7-C could promote DC maturation and combined with slit2 siRNA could promote polarization of M2 subtype macrophages to M1 subtype macrophages and then increase the proportion of effector T cells to remodel the tumor environment. In conclusion, T7-C with glioma targeting as a delivery system of slit2 siRNA showed a good therapeutic effect in the treatment of glioma after intranasal administration and had potential application prospects.Statement of significanceIn contrast to the existing literature that uses complex materials to deliver drugs across the blood-brain barrier (BBB) in an invasive manner for glioma treatment, we developed a simple, self-assembling siRNA delivery system (T7-C) based on brain tumor-targeted T7 peptide to treat glioma by intranasal administra-tion. T7-C/siRNA could reach the tumor site through the olfactory bulb route and adjust the "cold" tumor microenvironment to the "hot" tumor microenvironment and non-invasive intranasal delivery route could shorten the journey and reduce the loss of genetic drugs. Therefore, our design has good application prospects and is expected to serve as a general strategy for intranasal drug delivery in the treatment of brain tumors.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

H7K(R2)2-modified Ph-Sensitive Self-Assembled Nanoparticles Delivering Small Interfering RNA Targeting Hepatoma-Derived Growth Factor for Malignant Glioma Treatment

Single-component self-assembled RNAi nanoparticles functionalized with tumor-targeting iNGR delivering abundant siRNA for efficient glioma therapy.

T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.

Enhanced Nose-to-brain Delivery of Sirna Using Hyaluronan-Enveloped Nanomicelles for Glioma Therapy

Brain Tumor-Targeted Therapy by Systemic Delivery of Sirna with Transferrin Receptor-Mediated Core-Shell Nanoparticles.

PEI-Coated Fe₃O₄ Nanoparticles Enable Efficient Delivery of Therapeutic siRNA Targeting REST into Glioblastoma Cells

Intelligent Nanoparticles With pH-Sensitive Co-Delivery of Temozolomide and siEGFR to Ameliorate Glioma Therapy

A Simple Self-Assembly Nanomicelle Based on Brain Tumor-Targeting Peptide-Mediated Sirna Delivery for Glioma Immunotherapy Via Intranasal Administration

Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery.

Antitumoral Cascade-Targeting Ligand for IL-6 Receptor-Mediated Gene Delivery to Glioma

Hsp70-Targeting and Size-Tunable Nanoparticles Combine with PD-1 Checkpoint Blockade to Treat Glioma.

The siEGFR nanoplexes for the enhanced brain glioma treatment: Endoplasmic reticulum biomimetic strategy to induce homing effect and non-degradable intracellular transport

Single siRNA Nanocapsules for Effective siRNA Brain Delivery and Glioblastoma Treatment

Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A Sirna Delivery and Targeted Malignant Glioblastoma Therapy

Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth

Sustained and Targeted Delivery of Sirna/dp7-C Nanoparticles from Injectable Thermosensitive Hydrogel for Hepatocellular Carcinoma Therapy

Brain-targeting biomimetic nanoparticles for codelivery of celastrol and LY2157299 for reversing glioma immunosuppression

An RGD-modified MRI-visible Polymeric Vector for Targeted Sirna Delivery to Hepatocellular Carcinoma in Nude Mice.

Delivery Sirna With A Novel Gene Vector For Glioma Therapy By Targeting Gli1

Boosting RNAi Therapy for Orthotopic Glioblastoma with Nontoxic Brain-Targeting Chimaeric Polymersomes

Lipoprotein-biomimetic Nanostructure Enables Tumor-Targeted Penetration Delivery for Enhanced Photo-Gene Therapy Towards Glioma.